


Active Filter(s):
Details:
The collaboration aims to facilitate Chemistry, Manufacturing, and Control documentation for Lipella's drug candidate LP-10 (liposomal tacrolimus), aimed at treating hemorrhagic cystitis. LP-10 has been granted Orphan Drug Designation by the FDA.
Lead Product(s): Tacrolimus
Therapeutic Area: Urology Product Name: LP-10
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Lipella Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 17, 2023